MINNEAPOLIS--(BUSINESS WIRE)--March 27, 2006--BIOVIRx and IDT announced today an agreement intended to develop the oral rotavirus vaccine RotaShield(R) for commercialization. Worldwide, rotavirus gastroenteritis causes more than 2 million hospitalizations and up to 600,000 deaths annually in infants and young children. BIOVIRx has an exclusive worldwide license for RotaShield(R) and is planning global commercialization upon appropriate regulatory approvals. IDT currently has existing vaccine production capacity for RotaShield(R) and has initiated construction of a new manufacturing facility for expanded production of the vaccine. The new facility will be located at the IDT complex in Dessau-Tornau, Germany.
